{"filing":{"accession_number":"0001104659-26-117080","cik":"0001671502","ticker":"QNRX","company_name":"Quoin Pharmaceuticals Ltd.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"tm2627720d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926117080/tm2627720d1_8k.htm"},"events":[{"id":36243,"run_id":33406,"accession_number":"0001104659-26-117080","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Quoin Pharmaceuticals announced publication of a peer-reviewed manuscript on QRX003 for Netherton Syndrome, including positive compassionate-use case data (21 months of treatment with skin improvement from severe to clear and elimination of pruritus) and interim Phase 2/3 trial results (66.7% primary endpoint achievement). This represents a material clinical and scientific milestone for the company's lead investigational product, supporting its regulatory and commercial strategy.","company_name":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40585,"accession_number":"0001104659-26-117080","item_number":"7.01","item_title":"Regulation","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of a peer-reviewed manuscript on QRX003 for Netherton Syndrome, including positive compassionate-use case data (21 months of treatment with skin improvement from severe to clear and elimination of pruritus) and updates on the ongoing Phase 2/3 clinical trial (66.7% primary endpoint achievement in interim analysis, full recruitment expected by end of 2026, topline data expected Q2 2027). This is a material operational/clinical milestone for a late-stage specialty pharmaceutical company, as it represents peer-reviewed validation of the investigational drug's mechanism and clinical benefit, which would be significant to investors assessing the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:36:43.526277+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40587,"accession_number":"0001104659-26-117080","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of a peer-reviewed manuscript on QRX003 and presents a 21-month compassionate-use case report showing clinical improvement in a pediatric Netherton Syndrome patient, along with positive interim Phase 2/3 trial results (4 of 6 patients met primary endpoint, p=0.0087). This represents material clinical and scientific progress for a late-stage specialty pharmaceutical company's lead investigational product, affecting investor assessment of development trajectory and regulatory prospects, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:36:43.526277+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40585,"accession_number":"0001104659-26-117080","item_number":"7.01","item_title":"Regulation","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of a peer-reviewed manuscript on QRX003 for Netherton Syndrome, including positive compassionate-use case data (21 months of treatment with skin improvement from severe to clear and elimination of pruritus) and updates on the ongoing Phase 2/3 clinical trial (66.7% primary endpoint achievement in interim analysis, full recruitment expected by end of 2026, topline data expected Q2 2027). This is a material operational/clinical milestone for a late-stage specialty pharmaceutical company, as it represents peer-reviewed validation of the investigational drug's mechanism and clinical benefit, which would be significant to investors assessing the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:36:43.526277+00:00","company_name":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","filing_date":"2026-10-20"},{"id":40587,"accession_number":"0001104659-26-117080","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of a peer-reviewed manuscript on QRX003 and presents a 21-month compassionate-use case report showing clinical improvement in a pediatric Netherton Syndrome patient, along with positive interim Phase 2/3 trial results (4 of 6 patients met primary endpoint, p=0.0087). This represents material clinical and scientific progress for a late-stage specialty pharmaceutical company's lead investigational product, affecting investor assessment of development trajectory and regulatory prospects, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:36:43.526277+00:00","company_name":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","filing_date":"2026-10-20"}]}